What is Infigratinib: Uses, Dosage, Side Effects and More

Infigratinib is a targeted cancer medication that blocks specific proteins helping certain tumors grow. It's specifically designed to treat a rare type of bile duct cancer called cholangiocarcinoma when it has a particular genetic change. This oral medication works by interfering with cancer cell signals, essentially putting the brakes on tumor growth in carefully selected patients.

What is Infigratinib?

Infigratinib belongs to a class of drugs called kinase inhibitors. Think of it as a very specific key that fits into particular locks on cancer cells. It targets proteins called fibroblast growth factor receptors (FGFR), which can become overactive in certain cancers and fuel tumor growth.

This medication is what doctors call a precision medicine. It only works for patients whose tumors have specific genetic alterations involving FGFR genes. Before starting treatment, your doctor will test your tumor tissue to confirm you have the right genetic makeup for this drug to be effective.

What is Infigratinib Used For?

Infigratinib treats adults with advanced bile duct cancer (cholangiocarcinoma) that has specific FGFR genetic changes. Your doctor will only prescribe this medication if your cancer has already been treated with other therapies and has returned or spread to other parts of your body.

Bile duct cancer is quite rare, affecting the tubes that carry bile from your liver to your small intestine. When this cancer has FGFR alterations, infigratinib can help slow its growth and may shrink tumors in some patients. However, it's important to understand that this medication manages the disease rather than cures it.

Your oncologist will have confirmed through genetic testing that your tumor has the specific FGFR2 fusion or rearrangement that makes infigratinib potentially helpful. Without these genetic changes, the medication won't work for your particular cancer.

How Does Infigratinib Work?

Infigratinib works by blocking faulty signals that tell cancer cells to grow and multiply. In healthy cells, FGFR proteins help control normal cell growth. But in some cancers, these proteins become overactive, sending constant "grow" signals to cancer cells.

This medication is considered a moderately strong targeted therapy. It specifically interferes with the FGFR pathway, which is like cutting a specific wire in the cancer cell's communication system. When infigratinib blocks these signals, cancer cells may stop growing, shrink, or die.

Unlike chemotherapy that affects many different types of cells, infigratinib is designed to primarily target cancer cells with FGFR alterations. This targeted approach can mean fewer side effects than traditional chemotherapy, though it still requires careful monitoring.

How Should I Take Infigratinib?

Take infigratinib exactly as your doctor prescribes, typically once daily on an empty stomach. You'll need to avoid eating for at least one hour before and two hours after taking your dose. This helps your body absorb the medication properly.

Swallow the capsules whole with a full glass of water. Don't crush, chew, or open the capsules, as this can affect how the medication works. If you have trouble swallowing pills, talk to your healthcare team about strategies that might help.

Try to take your medication at the same time each day to maintain steady levels in your body. Many patients find it helpful to set a daily alarm or link taking their medication to a routine activity like brushing their teeth.

Your doctor will likely recommend following a low-phosphate diet while taking infigratinib. This means limiting foods high in phosphorus like dairy products, nuts, and certain meats. Your healthcare team will provide specific dietary guidelines to follow.

How Long Should I Take Infigratinib For?

You'll typically take infigratinib for as long as it continues to control your cancer and you can tolerate the side effects. Most patients follow a specific schedule: 21 days of taking the medication followed by 7 days off, which equals one treatment cycle.

Your doctor will monitor how well the medication is working through regular scans and blood tests. If your cancer stops responding to infigratinib or side effects become too difficult to manage, your doctor may recommend stopping the medication or switching to a different treatment.

Some patients take infigratinib for many months or even years, while others may need to stop sooner. The duration depends on your individual response, side effects, and overall health. Your oncologist will work with you to find the right balance between controlling your cancer and maintaining your quality of life.

What Are the Side Effects of Infigratinib?

Like all cancer medications, infigratinib can cause side effects, though not everyone experiences them. Most side effects are manageable with proper monitoring and supportive care from your healthcare team.

Here are the most common side effects you might experience:

• Fatigue and weakness
• Nail changes, including nail loss or brittle nails
• Mouth sores or dry mouth
• Diarrhea or constipation
• Decreased appetite
• Hair thinning or changes in hair texture
• Skin dryness or rash
• Joint or muscle pain

Your doctor will monitor you closely for more serious but less common side effects. These require immediate attention and may include severe eye problems, kidney issues, or dangerous changes in your blood chemistry.

One particular concern with infigratinib is retinal detachment, where the light-sensitive tissue at the back of your eye separates from underlying layers. You'll need regular eye exams during treatment, and you should report any sudden vision changes immediately.

High phosphate levels in your blood can also occur, which is why following a low-phosphate diet is so important. Your healthcare team will check your blood phosphate levels regularly and may prescribe medications to help keep them in a safe range.

Who Should Not Take Infigratinib?

Infigratinib isn't suitable for everyone, and certain conditions may make it unsafe for you to take this medication. Your doctor will carefully review your medical history before prescribing it.

You should not take infigratinib if you're allergic to the medication or any of its ingredients. Additionally, this medication isn't recommended during pregnancy or while breastfeeding, as it could harm your baby.

Several health conditions require special caution or may prevent you from taking infigratinib safely:

• Severe kidney disease
• Existing eye problems, especially retinal issues
• Heart rhythm disorders
• Liver disease
• History of kidney stones
• Certain inherited conditions affecting phosphate metabolism

Your doctor will also consider other medications you're taking, as some drugs can interact with infigratinib. Be sure to tell your healthcare team about all prescription medications, over-the-counter drugs, and supplements you use.

Infigratinib Brand Name

Infigratinib is sold under the brand name Truseltiq. This is the only brand name currently available for this medication in the United States.

When you receive your prescription, you'll see "Truseltiq" on the bottle label along with the generic name "infigratinib." Both names refer to the same medication, so don't worry if you see either one used in your medical records or by your healthcare team.

Infigratinib Alternatives

Currently, there are limited alternatives to infigratinib for treating bile duct cancer with FGFR alterations. Other FGFR inhibitors like pemigatinib might be options in some cases, but the choice depends on your specific situation and cancer genetics.

If infigratinib stops working or causes intolerable side effects, your oncologist might consider other targeted therapies, immunotherapy drugs, or traditional chemotherapy. The best alternative depends on your cancer's genetic profile, previous treatments, and overall health.

Clinical trials investigating new treatments for bile duct cancer might also be an option. Your oncologist can help you explore whether any research studies might be appropriate for your situation.

Is Infigratinib Better Than Other FGFR Inhibitors?

Comparing infigratinib to other FGFR inhibitors isn't straightforward because each medication has been studied in different patient populations and clinical settings. What matters most is finding the right drug for your specific cancer and situation.

Infigratinib was specifically studied and approved for bile duct cancer with FGFR2 alterations. Other FGFR inhibitors like pemigatinib have been studied in broader cancer types but may have different side effect profiles or effectiveness rates.

Your oncologist will consider factors like your cancer's specific genetic changes, your overall health, previous treatments, and potential side effects when choosing the best FGFR inhibitor for you. The "better" choice is the one that works best for your individual circumstances.